This question can be resolved by analyzing the Th1/Th17/Th2-type of T-cell reactivity against PLP, particularly against PLP139-151 and PLP175-194 epitopes by PBLs of HLA-DR15+ MS patients, compared to the Th1/Th17/Th2-type response by their DRB1*1501- and DQB1*0602-restricted T-cells reactive against these epitopes. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.